Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Ivonescimab Plus Chemotherapy in Non–Small Cell Lung Cancer With EGFR Variant
Wen‐Feng Fang, Yuanyuan Zhao, Yongzhong Luo, et al.
JAMA (2024) Vol. 332, Iss. 7, pp. 561-561
Open Access | Times Cited: 37

Showing 1-25 of 37 citing articles:

Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
Anwen Xiong, Lei Wang, Jianhua Chen, et al.
The Lancet (2025) Vol. 405, Iss. 10481, pp. 839-849
Closed Access | Times Cited: 4
The changing treatment landscape of EGFR-mutant non-small-cell lung cancer
Fei Zhou, Haoyue Guo, Yang Xia, et al.
Nature Reviews Clinical Oncology (2024)
Closed Access | Times Cited: 10
Immunotherapy efficacy between exon 19 deletion and exon 21 L858R mutation in advanced EGFR mutant non-small-cell lung cancer: a direct and indirect meta-analysis
Zihong Chen, Lanlan Pang, Yang Yuwen, et al.
Translational Lung Cancer Research (2025) Vol. 14, Iss. 2, pp. 422-430
Open Access | Times Cited: 1
Ivonescimab: First Approval
Sohita Dhillon
Drugs (2024) Vol. 84, Iss. 9, pp. 1135-1142
Closed Access | Times Cited: 7
Antibodies to watch in 2025
Silvia Crescioli, Hélène Kaplon, Lin Wang, et al.
mAbs (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 4
Efficacy and safety of camrelizumab plus famitinib in patients with previously treated non-small-cell lung cancer: a single-arm, phase II trial
Ming Gao, Xia Zhang, Huan Yan, et al.
Therapeutic Advances in Medical Oncology (2025) Vol. 17
Open Access
CNS outcomes of osimertinib plus chemotherapy in patients with EGFR mutation positive lung cancer beyond osimertinib progression
Wesley K.Y. Wong, Kevin Mok, G. Tsui, et al.
Clinical Lung Cancer (2025)
Closed Access
Efficacy and Safety of Ivonescimab in the Treatment of Advanced Non-small Cell Lung Cancer (NSCLC): A Systematic Review
Alzahra'a Al matairi, Bara M Hammadeh, Abdullah Yousef Aldalati, et al.
Cureus (2025)
Open Access
Unveiling the immunomodulatory dance: endothelial cells’ function and their role in non-small cell lung cancer
Sophia Daum, Lilith Decristoforo, Mira Mousa, et al.
Molecular Cancer (2025) Vol. 24, Iss. 1
Open Access
The Devil Lies in the Details: An Analysis of Six Oncology Randomised Controlled Trials
Alfonso Dueñas‐González, Leticia Bornstein-Quevedo, Francisco Gutiérrez-Delgado
(2025)
Closed Access
Targeting the Tumor Microenvironment in EGFR-Mutant Lung Cancer: Opportunities and Challenges
Jeong Uk Lim, Junyang Jung, Yeon Wook Kim, et al.
Biomedicines (2025) Vol. 13, Iss. 2, pp. 470-470
Open Access
Case report: Aumolertinib plus gumarontinib in a patient with EGFR mutated non-small-cell lung cancer harboring acquired MET amplification following progression on afatinib plus crizotinib
Jia-Jun Hui, Shan Ding, Bao‐Dong Qin, et al.
Frontiers in Pharmacology (2025) Vol. 16
Open Access
A randomised non-comparative phase II study of atezolizumab, bevacizumab and chemotherapy in EGFR-mutant NSCLC with acquired resistance – The ETOP 15-19 ABC-lung trial
Ross A. Soo, Urania Dafni, Martin Früh, et al.
Lung Cancer (2025) Vol. 202, pp. 108454-108454
Closed Access
Resistance to Immunotherapy in Non-small Cell Lung Cancer: Unraveling Causes, Developing Effective Strategies, and Exploring Potential Breakthroughs
Shuang Dong, Xiaoyu Li, Qing Huang, et al.
Drug Resistance Updates (2025) Vol. 81, pp. 101215-101215
Closed Access
Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2024.3
Dwight H. Owen, Nofisat Ismaila, Amith Ahluwalia, et al.
Journal of Clinical Oncology (2025)
Closed Access
Ivonescimab in advanced NSCLC: is progression-free survival enough, or are overall survival data also needed?
K. Nathan Sankar, Karen L. Reckamp
The Lancet (2025) Vol. 405, Iss. 10481, pp. 757-759
Closed Access
Safety, Pharmacokinetics, and Pharmacodynamics Evaluation of Ivonescimab, a Novel Bispecific Antibody Targeting PD‐1 and VEGF, in Chinese Patients With Advanced Solid Tumors
Feng‐Hua Wang, Xiaoli Wei, Yulong Zheng, et al.
Cancer Medicine (2025) Vol. 14, Iss. 6
Open Access
Next-generation sequencing for guiding matched targeted therapies in people with relapsed or metastatic cancer
Farasat Kazmi, Nipun Shrestha, Tiaotiao Liu, et al.
Cochrane library (2025) Vol. 2025, Iss. 3
Open Access
Recent advances in therapeutic strategies for non-small cell lung cancer
Po‐Lan Su, Naoki Furuya, Atif Asrar, et al.
Journal of Hematology & Oncology (2025) Vol. 18, Iss. 1
Open Access
Traitement standard des cancers bronchiques non à petites cellules métastatiques mutés EGFR en première ligne et à progression
Antoine Lefèvre, Benjamin Besse
Bulletin du Cancer (2025) Vol. 112, Iss. 3, pp. 3S75-3S85
Closed Access
Research Advances in Drug Therapy after Resistance to Third-Generation EGFR-TKIs
东京 肖
Advances in Clinical Medicine (2025) Vol. 15, Iss. 04, pp. 204-210
Closed Access
Ivonescimab in non-small cell lung cancer: harmonizing immunotherapy and anti-angiogenesis
Yan Zhang, Xinyu Liu, Shengxiang Ren
Expert Opinion on Biological Therapy (2025)
Closed Access
Bispecific Antibodies in Hematologic and Solid Tumors: Current Landscape and Therapeutic Advances
Lorenzo Guidi, Julian Etessami, Carmine Valenza, et al.
American Society of Clinical Oncology Educational Book (2025) Vol. 45, Iss. 3
Closed Access
Benmelstobart plus anlotinib in patients with EGFR-positive advanced NSCLC after failure of EGFR TKIs therapy: a phase I/II study
Meiqi Shi, Ping Chen, Bin Cui, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 2
Treatment sequences in EGFR mutant advanced NSCLC
Mylène Wespiser, Aurélie Swalduz, M. Pérol
Lung Cancer (2024) Vol. 194, pp. 107895-107895
Closed Access | Times Cited: 1
Page 1 - Next Page

Scroll to top